Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report

QR Code

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report

Yuji Kitaichi,1 Takeshi Inoue,1 Nobuyuki Mitsui,1 Shin Nakagawa,1 Rie Kameyama,1 Yoshiyuki Hayashishita,1 Tohru Shiga,2 Ichiro Kusumi,1 Tsukasa Koyama1 1Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; 2Department of Nuclear Medicine, Graduate School of Med...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Kitaichi Y, Inoue T, Mitsui N, Nakagawa S, Kameyama R, Hayashishita Y, Shiga T, Kusumi I, Koyama T
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2013
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/fd61bbf02b9a4995b8c48db7ac1b955d
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

The structural equation analysis of childhood abuse, adult stressful life events, and temperaments in major depressive disorders and their influence on refractoriness
par: Toda H, et autres
Publié: (2015)

Effect of triiodothyronine (T3) augmentation of acute milnacipran administration on monoamine levels: an in vivo microdialysis study in rats
par: Kitaichi Y, et autres
Publié: (2012)

Confirmation of the factorial structure of the Japanese short version of the TEMPS-A in psychiatric patients and general adults [Corrigendum]
par: Nakato Y, et autres
Publié: (2017)

Confirmation of the factorial structure of the Japanese short version of the TEMPS-A in psychiatric patients and general adults
par: Nakato Y, et autres
Publié: (2016)

Differences between bipolar and unipolar depression on Rorschach testing
par: Kimura H, et autres
Publié: (2013)

Prevalence of Comorbid Anxiety Disorders and Their Associated Factors in Patients with Bipolar Disorder or Major Depressive Disorder
par: Inoue T, et autres
Publié: (2020)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
par: Aoki A, et autres
Publié: (2014)

Desvenlafaxine in the treatment of major depressive disorder
par: Maria Teresa C Lourenco1, et autres
Publié: (2009)

Predictors of social anxiety disorder with major depressive episodes among Japanese university students.
par: Shinya Watanabe, et autres
Publié: (2021)

Anatomical and functional brain abnormalities in unmedicated major depressive disorder
par: Yang X, et autres
Publié: (2015)

Psychiatric comorbidities in patients with major depressive disorder
par: Thaipisuttikul P, et autres
Publié: (2014)

The Association Between Hypoxia Improvement and Electroconvulsive Therapy for Major Depressive Disorder
par: Bian Z, et autres
Publié: (2021)

Plasma complement component 4 increases in patients with major depressive disorder
par: Wei J, et autres
Publié: (2017)

Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder
par: Huang YC, et autres
Publié: (2018)

Serum Exosome-Derived miR-139-5p as a Potential Biomarker for Major Depressive Disorder
par: Liang JQ, et autres
Publié: (2020)

Elevated peripheral blood glutamate levels in major depressive disorder
par: Inoshita M, et autres
Publié: (2018)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
par: Mazen K Ali, et autres
Publié: (2011)

Augmentation treatment in major depressive disorder: focus on aripiprazole
par: J Craig Nelson, et autres
Publié: (2008)

Mitochondrial dysfunction, oxidative stress, and major depressive disorder
par: Tobe EH
Publié: (2013)

Levomilnacipran for the treatment of major depressive disorder: a review
par: Asnis GA, et autres
Publié: (2015)

Effect of aripiprazole on non-24-hour sleep–wake rhythm disorder comorbid with major depressive disorder: a case report
par: Matsui K, et autres
Publié: (2017)

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
par: Otsubo T, et autres
Publié: (2018)

Atrophic Corpus Callosum Associated with Altered Functional Asymmetry in Major Depressive Disorder
par: Ran S, et autres
Publié: (2020)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
par: Huang Q, et autres
Publié: (2016)

Major depressive disorder: mechanism-based prescribing for personalized medicine
par: Saltiel PF, et autres
Publié: (2015)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
par: Zhang XF, et autres
Publié: (2015)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
par: Alvarez E, et autres
Publié: (2014)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
par: Bernhard T Baune
Publié: (2008)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
par: Kamijima K, et autres
Publié: (2013)

Disturbances of mitochondrial parameters to distinguish patients with depressive episode of bipolar disorder and major depressive disorder
par: Zvěřová M, et autres
Publié: (2019)

The Combination of Serum BDNF, Cortisol and IFN-Gamma Can Assist the Diagnosis of Major Depressive Disorder
par: Chen S, et autres
Publié: (2021)

Disrupted Brain Entropy And Functional Connectivity Patterns Of Thalamic Subregions In Major Depressive Disorder
par: Xue SW, et autres
Publié: (2019)

Major depressive disorders in chronic hemodialysis patients in Nazareth: identification and assessment
par: Armaly Z, et autres
Publié: (2012)

Getting the balance right: Established and emerging therapies for major depressive disorders
par: Bojana Perovic, et autres
Publié: (2010)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
par: Yoshimura R, et autres
Publié: (2017)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
par: Kamijima K, et autres
Publié: (2013)

A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
par: A Ahmadi Ahangar, et autres
Publié: (2002)

Quality of life in euthymic patients with unipolar major depressive disorder and bipolar disorder
par: Bo Q, et autres
Publié: (2019)

The level of IL-6 was associated with sleep disturbances in patients with major depressive disorder
par: Wang M, et autres
Publié: (2019)

Sex differences in gut microbiota in patients with major depressive disorder
par: Chen JJ, et autres
Publié: (2018)